Central cannabinoid (CB₁) receptor antagonists may have potential in the treatment of a number of diseases such as neuroinflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders.¹ (R)-SLV 319 is the inactive enantiomer of SLV 319 with 100-fold less affinity for the CB₁ receptor. SLV 319 is a potent and selective CB₁ receptor antagonist with K_i values of 7.8 and 7,943 nM for CB₁ and peripheral cannabinoid (CB₂) receptors, respectively.¹ SLV 319 is less lipophilic (log P = 5.1) and therefore more water soluble than other known CB₁ receptor ligands.²

≥98%

Store at -20℃

1.Lange, J.H.M.,Coolen, H.K.A.C.,van Stuivenberg, H.H., et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB₁ cannabinoid receptor antagonists. Journal of Medicinal Chemistry 47(3), 627-643 (2004).

2.Lange, J.H.M.,van Stuivenberg, H.H.,Veerman, W., et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB₁ receptor antagonists with lower lipophilicity. Bioorganic & Medicinal Chemistry Letters 15, 4794-4798 (2005).